Online Reviews Show Patients Seek Strong Patient-Provider Communication

Courtesy of Sarai Rodriguez, Patient Engagement HIT, Xtelligentmedia.com

Online provider reviews are often tied to strong patient-provider communication, with patients highlighting thorough procedure explanations when leaving five-star reviews.

The study, which looked at plastic surgeons in particular, also showed that clinician competence and good clinical outcomes are also important.

The rise of healthcare consumerism in recent years has impacted the way patients interact with providers. A growing preference for self-service options and digital engagement has heightened the need for a positive online provider presence.

The report, which examined around 5,210 Yelp reviews of plastic surgery providers from 49 cities across the United States, sheds light on what patients value most in their healthcare experiences

Unsurprisingly, surgical outcomes topped the list of factors influencing positive reviews for plastic surgery providers.

Patients seeking surgical services were keen to emphasize their satisfaction with both injectable and surgical outcomes, reinforcing that patient satisfaction hinges largely on whether their healthcare expectations were met.

Yet, patients did not only focus on outcomes. Five-star reviews emphasized the value of comprehensive and clear communication from physicians about procedures. Patients praised doctors who took time during initial consultations to answer all questions, explain the procedure in detail, and set realistic expectations about the recovery period.

“Patients with positive experiences emphasized having results that looked natural and matched the look they had discussed with the physician prior to surgery,” senior author Brent R. DeGeorge, MD, PhD, of the University of Virginia, Charlottesville, wrote:

“Patients felt most comfortable with physicians who gave thorough explanations of the procedures beforehand, often spending several hours over multiple consultation sessions.”

The report revealed that provider interaction is not the only determinant in shaping patient satisfaction. Interactions with office staff, scheduling difficulties, billing or insurance problems, and extended wait times significantly swayed whether patients left positive or negative reviews.

Past research has highlighted that lengthy wait times can be a turn-off for patients, emphasizing the importance of managing schedules to prevent delays.

Patients also gave low ratings to providers who were not cost-conscious.

Negative experiences at a provider’s office not only jeopardize patient satisfaction but can also tarnish the reputation of the provider among potential future clients, especially if negative feedback is shared online.

That can have consequences for patient volumes as more patients consult online reviews before picking a new provider.

A March 2023 survey revealed that 46 percent of patients lean on online reviews when choosing healthcare providers. As loyalty is becoming less of a deciding factor, an adverse patient experience can swiftly steer consumers to seek alternatives.

It may be helpful for providers to assess the factors that sway online provider reviews. One 2022 survey from Wakefield Research and Kyruus showed that a reputation for providing quality care ranks within the top five critical characteristics when patients assess potential providers.

With many patients relying on online reviews for provider selection, poor patient experience can easily provoke a shift in consumer choice.

The Wakefield Research/Kyruus report suggested that positive reviews could be the tipping point between success and failure for some organizations. Just over a quarter, or 26 percent of patients, will seek another provider after encountering three negative reviews. Moreover, 56 percent will dismiss a provider with an average rating of less than four stars.

How to Use Teamwork to Create a Culture of Patient Safety

Courtesy of Sara Heath, Senior Editor, Xtelligentmedia.com

Patient safety efforts need to start for health system boards, but be carried out by senior leadership and sustained by frontline staff.

Mike Seim, MD, the senior vice president, and chief quality officer at WellSpan Health, can hardly remember the last time some of the system’s hospitals had central line-associated bloodstream infections or catheter- 13 associated UTIs. It’s been a long time since those patient safety events, he said, mostly because of WellSpan’s overall culture of patient safety.

It might seem obvious why a healthcare organization would want to address patient safety. Patient safety is one of the most paramount features of the patient experience. Patients go to the hospital because they are sick and want to get better, and when an adverse patient safety event occurs, it gets in the way of good outcomes and, in many cases, a good patient experience.

But despite that, patient safety can often feel elusive. In January 2023, Mass General Brigham and CRICO, the medical professional liability insurer for the Harvard medical community and its affiliated organizations, found that adverse patient safety events are still somewhat common.

Patient safety events occurred in a quarter of inpatient hospitalizations in 2018, the team wrote in the New England Journal of Medicine. Of those patient harms, 23 percent were deemed preventable, and 32 percent were marked with high clinical severity. According to Seim, the problem isn’t that healthcare organizations don’t care about or aren’t trying hard enough to achieve zero harm. But reducing patient safety is a team effort, and it can be difficult to orchestrate a consistent strategy across an entire organization. “In most health systems, everyone talks about patient safety,” Seim said in an interview with PatientEngagementHIT.

“But how do you create that overarching strategy to actually achieve measurable outcome results?” The Pennsylvania-based WellSpan knew a culture of patient safety was going to have to start at the top with buy-in from the health system’s board of directors and CEO. As a group, they developed a set of measurable outcome goals for the organization’s frontline staff to adopt.

WellSpan didn’t exactly reinvent the wheel when doing this. Like most organizations, WellSpan was concerned with measures like hospital-acquired conditions, falls with injuries, and other events linked to CMS and other regulatory agencies. The health system also used the Pennsylvania Safety Authority’s requirements for serious event reporting.

As those goals moved down the line to frontline staff, Seim said it was time to implement a new, leaner management strategy.

“Oftentimes, across larger health systems, one area of the organization may solve a problem, but it never gets disseminated or spread across the health system,” Seim explained. “Our approach was to really create a formal process to identify safety concerns, figure out what the actual true root cause was of the problem, then commit the team’s talents and resources to solving the problem to root and, ultimately, to disseminate and spread across the organization.”

Seim and his team started with WellSpan’s safety reporting system, which they rebranded into a safety first system.

“We focused on rebranding it to the concept of safety first, so it didn’t feel like a punitive reporting system,” he noted.

“It was trying to change the mindset of being reactive, so responding to problems after they occurred, to encouraging team members to have the mindset of reporting anything that could cause a problem.”

The safety-first reporting system was the result of multiple listening sessions with team members who stated that the shift in mindset helped them feel psychologically safe in reporting events. After all, it can be difficult to report when you or someone else has made a mistake for fear of disciplinary action.

“We wanted to create a culture where people not only felt they could, but that they were expected, and it was a requirement of their job that they raise any potential safety concern or potential harm,” Seim said.

With that, the organization also implemented its six-tier huddle system. Starting at 6:45 a.m., frontline staff meet to discuss any potential patient harm that could fall down the line with the intent of putting an end to them before they begin. Those huddles work up the chain of command until the sixth and final one happens at 9:15 a.m. with participation from WellSpan’s CEO.

These huddles, plus the entire work to achieve better patient safety, don’t start and end with the clinical team, Seim clarified. Every team member in the health system is expected to participate in these patient safety huddles.

“Our goal is to link every single team member to safety,” he stressed. Those in patient financial services, for example, are tied to patient safety because some folks might forego care if they
don’t get the right information about billing.


“Every team, from food services, environmental services, and patient financial services to the care teams, huddle every day and raise any concerns that could contribute to a less-than-ideal experience and/or safety,” Seim added.

The huddles and the rebrand have had a significant impact on patient safety. WellSpan went from 20,000 to more than 41,000 events being recorded within the safety-first system. That coincided with a nearly 50 percent decrease in serious safety events. It’s been nearly a thousand days since the last central line associated bloodstream infection in some facilities and nearly a year since catheter-associated UTIs in other ICUs, Seim added.

That’s not just because it’s easier and more psychologically safe for team members to report potential incidents.

WellSpan has prioritized transparency and follow-through on the part of its senior leadership, Seim pointed out, and it’s provided a bedrock of support for frontline staff.

When a team member contributes to the safety-first system, it’s on the senior leadership to uncover what process issues may have contributed to the issue and how to revise that process to stop the issue from snowballing and prevent it again in the future.

“It also goes back to us talking regularly about most errors happen because, as a system, we didn’t support team members with our process,” Seim stated. “We have to go back and be willing to listen to the frontline team members about why this process was set up to fail and what needs to happen to fix it as a team. It starts with a sense of humility and inquiry as leaders to really say, ‘how did we fail as a system to allow this mistake to happen to a patient?’

”This level of engagement and accountability from senior leadership has helped bolster the confidence of other frontline staff members. The more team members see they won’t get fired for a patient safety event, the more comfortable they feel participating in the safety first system, Seim said. Moreover, WellSpan has gone to lengths to ensure team members receive praise when they stop the line of adverse events.

“Our desire is to really celebrate team members when they do stop the line, even if it doesn’t turn out to be a problem,” Seim explained. “We have what we call our Heads Up Speak Up Awards, where we celebrate everyone who did stop the line or identified maybe even a potential problem.”

Of course, patients themselves are important members of the care team, Seim acknowledged. Shifting the culture of patient safety has also meant empowering the patient and their family members or caregivers.

“We do give our patients the opportunity to recognize team members. We have a very strong philosophy of disclosure,” Seim concluded. “You actually build more trust with patients when you’re transparent, and so really engaging our patients and being transparent with either a patient or a team member, a patient team member or family member, whenever anything adverse happens.”

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.

Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan

Datascope/Maquet/Getinge Recalls Cardiosave Hybrid and Rescue Intra-aortic Balloon Pumps (IABPs) for Unexpected Shutdowns

The Cardiosave Hybrid Intra-Aortic Balloon Pump (IABP) and the Cardiosave Rescue IABP are electromechanical systems used to inflate and deflate intra-aortic balloons. These systems provide temporary support to the left ventricle through counter pulsation. Once the balloon is positioned in the aorta, the pump is set to work in synchrony with the electrocardiogram or arterial pressure waveform to make the balloon inflate and deflate at the right time during the cardiac cycle.

Datascope/Maquet/Getinge is recalling the Cardiosave Hybrid and Rescue Intra-aortic Balloon Pumps (IABPs) because they may shutdown unexpectedly due to electrical failures in the Power Management Board or Solenoid Board (Power Source Path).

Using an affected pump may cause serious adverse health events, including unstable blood pressure, injury (for example: inadequate blood supply or a vital organ injury), and death. Datascope/Maquet/Getinge reported 26 complaints. There have been no reports of injuries, or death.

On June 5, 2023, Datascope/Maquet/Getinge sent all affected customers an Important Medical Device Advisory.

The letter requested customers to:
• Ensure there is an alternative IABP available to continue therapy.
• Provide alternative hemodynamic support if there is no other means to continue
counterpulsation therapy.
Customers with questions about this recall should contact their Datascope/Maquet/Getinge
representative or call Datascope/Maquet/Getinge Technical Support at 1-888-943-8872, options 4, 2, 1,
Monday through Friday, between the hours of 8:00 a.m. and 6:00 p.m. (Eastern Time).

Product Models:

o Cardiosave Hybrid

o Cardiosave Rescue

• Distribution Dates: March 6, 2012 to May 19, 2023

• Devices Distributed in the U.S.: 4586

• Date Initiated by Firm: June 5, 2023

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA’s MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

• Complete and submit the report online
• Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

TYRUKO

FDA Approves First Biosimilar to Treat Multiple Sclerosis

The U.S. Food and Drug Administration has approved Tyruko (natalizumab-sztn), the first biosimilar to Tysabri (natalizumab) injection for the treatment of adults with relapsing forms of multiple sclerosis (MS).

Tyruko (natalizumab-site) is an injectable integrin receptor antagonist that is a biosimilar to Tysabri (natalizumab) that may be used to treat adults with relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease) or moderate to severe Crohn’s disease (usually after other treatments have been tried).

Patients who are allergic to natalizumab or have ever had PML should not receive Tyruko. Tyruko is only available from a certified pharmacy under a special program called the Tyruko REMS Program. Patients must be registered in the program and understand the risks and benefits of taking this medicine.

Read more…

EYLEA HD™

FDA Approves Eylea HD (aflibercept) Injection 8mg for Treatment of wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Eylea HD (aflibercept) Injection 8mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). The recommended dose for Eylea HD is 8mg (0.07mL of 114.3mg/mL solution) every four weeks (monthly) for the first three months across all indications, followed by 8mg every 8 to 16 weeks (2 to 4 months) in wAMD and DME and every 8 to 12 weeks (2 to 3 months) for DR.

Eylea is a long-acting injectable form of aflibercept that only needs to be given by a healthcare provider once every 2 to 4 months after an initial dosing period. It is used to treat the following conditions:

• Neovascular (Wet) Age-Related Macular Degeneration (AMD) – a condition where new blood vessels grow under the retina where they leak blood and fluid.

• Macular Edema Following Retinal Vein Occlusion (RVO) – a swelling in the retina caused by a blockage in the blood vessels.

• Diabetic Macular Edema (DME) – a build-up of fluid in the retina that is caused by leaking blood vessels.

• Diabetic Retinopathy (DR) – an eye disorder in diabetics that can lead to a buildup of fluid in the retina and cause blindness.

• Retinopathy of Prematurity (ROP) – an eye condition in premature babies that affects the retina.

Read more…

VEOPOZ

Regeneron Wins FDA Approval for Rare Immune

Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Veopoz™ (pozelimab-bbfg) for the treatment of adult and pediatric patients 1 year of age and older with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy.

CHAPLE is an ultra-rare and life-threatening hereditary immune disease driven by an overactivation of the complement system. In healthy individuals, the complement system is a mechanism for destroying microbes. However, those living with CHAPLE are unable to regulate complement activity due to mutations in their CD55 gene. Without proper CD55 regulation, the complement system may attack normal cells, causing damage to blood and lymph vessels along the upper digestive tract and leading to the loss of circulating proteins. There are fewer than 10 patients with CHAPLE disease identified in the U.S. Veopoz is a fully human, monoclonal antibody G4 (IgG4) that blocks the activity of complement factor C5 to regulate the complement pathway and relieve the symptoms of CHAPLE disease.

Read more…

SOHONOS™

FDA Approves Sohonos (palovarotene) for the Treatment of Fibrodysplasia Ossificans Progressiva

Ipsen has announced approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossification (HO) in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).

FOP impacts the lives of an estimated 400 people in the U.S. and 900 people globally. As the disease continuously progresses with flare-up episodes causing rapid bone growth, HO severely restricts mobility and function. Most people living with FOP inevitably lose the ability to eat and drink on their own, cannot provide self-care or use the restroom themselves, and are unable to maintain employment. By the age of 30 years old, the majority of people with FOP require a wheelchair and full-time caregiver assistance. The management of FOP has previously been limited to palliative care and ultimately, FOP shortens the median life expectancy to 56 years. Untimely death is often caused by bone formation around the ribcage leading to breathing problems and cardiorespiratory failure, or falls resulting in fractures or head injuries because joint ankylosis prevents bracing from a fall.

Sohonos is an oral medicine with particular selectivity for the gamma subtype of retinoic-acid receptors, which are an important regulator of skeletal development and ectopic bone in the retinoid signaling pathway. The medicine is designed to mediate the interactions between the receptors, growth factors and proteins within the retinoid signaling pathways to reduce new abnormal bone formation in FOP. The recommended dosing for Sohonos includes a chronic daily dosage of 5mg (or weight-based equivalent for pediatric patients under 14 years of age), which can be modified/increased for flare-up symptoms.

Sohonos may be prescribed immediately in the U.S. for eligible patients. To ensure access to Sohonos for eligible individuals in the U.S., Ipsen Cares patient support program is available as a resource to people living with FOP and their caregivers to provide educational support and address coverage, access and reimbursement questions (1-866-435-5677).

Read more…

ELREXFIO

FDA Grants Accelerated Approval for Elrexfio (elranatamab-bcmm) for Relapsed or Refractory Multiple Myeloma

The U.S. Food and Drug Administration granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma (R/R MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

As with all FDA accelerated approvals, continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Elrexfio is the first FDA-approved BCMA-directed therapy that can be dosed once every 2 weeks after an initial 24 weeks of weekly therapy. Approval of Elrexfio was based on data from the open-label, single-arm, multicenter Phase 2 MagnetisMM-3 trial. The trial included adults with R/R MM who had previously received and were refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody. Patients in Cohort A of the study were naïve to BCMA-directed therapy, while those in Cohort B had received prior BCMA-directed therapy. Among the 97 patients in Cohort A who had received four or more prior lines of therapy, the overall response rate was 58% after a median follow-up of 11.1 months, the duration of response was not reached, and the median time to first response was 1.2 months. Among the 63 patients in Cohort B who received four or more prior lines of therapy, the ORR was 33% after a median follow-up of 10.2 months.

Read more…

HEPZATO® KIT

FDA Approves Hepzato Kit (melphalan) Hepatic Delivery System for the Treatment of Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

Delcath Systems, Inc., has announced that the US Food and Drug Administration (FDA) approved Hepzato Kit (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

mUM is a rare and aggressive form of metastatic cancer with a U.S. incidence of approximately 1,000 cases per year. Ninety percent of mUM involves the liver, and liver failure is often the cause of death. National Comprehensive Cancer Network (NCCN) guidelines recommend liver-directed therapies for mUM patients with liver metastases. Hepzato Kit is the only liver-directed therapy approved by the FDA for the treatment of mUM and percutaneous hepatic perfusion (PHP), the procedure enabled by Hepzato Kit, is already included in the NCCN guidelines.

Hepzato Kit is a combination product that administers HEPZATO (melphalan), a well-known and long-approved chemotherapeutic agent, directly to the liver through Delcath’s novel device delivery system, the Hepatic Delivery System (HDS), which permits higher drug exposure in target tissues while limiting systemic toxicity. The use of the HDS allows a healthcare provider team to surgically isolate the liver while the hepatic venous blood is filtered during melphalan infusion and subsequent washout during a Percutaneous Hepatic Perfusion (PHP) procedure.

Read more…

ELREXFIO™

FDA Grants Accelerated Approval for Elrexfio (elranatamab-bcmm) for Relapsed or Refractory Multiple Myeloma

Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Elrexfio™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

• The approval of Elrexfio (elranatamab-bcmm) is based on clinically meaningful response rates and duration of response from Phase 2 MagnetisMM-3 study.

• Elrexfio is the first off-the-shelf (ready-to-use) fixed-dose subcutaneous BCMA-directed agent in the U.S. with the option for every-other-week long-term dosing after 24 weeks of weekly treatment.

• Pfizer continues to advance the MagnetisMM clinical program to expand Elrexfio into earlier lines of treatment, both as monotherapy and in combination with standard or novel therapies.

Used to treat multiple myeloma (MM), which is a type of blood cancer that affects plasma cells made in the bone marrow, Elrexfio is a B-cell maturation antigen (BCMA) CD3-targeted bispecific antibody (BsAb). Elrexfio binds to the B-cell maturation antigen surface (BCMA) of multiple myeloma cells and binds to the CD3 receptor on the T-cells.

Read more…